Results 101 to 110 of about 15,810 (189)

Activity of ceftolozane/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART – Brazil), 2018‒2021

open access: yesBrazilian Journal of Infectious Diseases
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators ...
Amanda Azevedo Bittencourt   +5 more
doaj   +1 more source

Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.

open access: yes, 2018
Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.
Brian D. Johnston (580892)   +2 more
core   +1 more source

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

open access: yesBMC Health Services Research
Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens.
Risako Takaya   +3 more
doaj   +1 more source

ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa [PDF]

open access: yes, 2019
To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL- producing Escherichia coli and Pseudomonas aeruginosa strains.Methods: A series of ESBL ...
Ortiz de la Rosa, José-Manuel   +2 more
core  

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

open access: yes, 2018
The activities of ceftolozane-tazobactam and comparator agents against organisms deemed to be the cause of pneumonia among patients hospitalized in the United States during 2013 to 2015 were evaluated.
Mariana Castanheira   +4 more
core   +1 more source

Clinical characteristics, microbiology data and outcome of patients treated with ceftolozane/tazobactam or ceftazidime/avibactam during the study period.

open access: yes, 2018
Clinical characteristics, microbiology data and outcome of patients treated with ceftolozane/tazobactam or ceftazidime/avibactam during the study period.
Juri Katchanov (5095268)   +8 more
core   +1 more source

Antimicrobial susceptibility and resistance mechanisms to antipseudomonal β-lactams in Pseudomonas aeruginosa isolates from blood

open access: yesMicrobiology Spectrum
Bloodstream infection caused by Pseudomonas aeruginosa with antimicrobial resistance can be difficult to treat. Herein, we investigated antimicrobial susceptibility to major antipseudomonal β-lactams and analyzed the relationship between resistance ...
Mika Murata   +7 more
doaj   +1 more source

L2 β-lactamase contributes to ceftolozane-tazobactam resistance in <i>Pseudomonas aeruginosa</i>. [PDF]

open access: yesAntimicrob Agents Chemother
Garai P   +7 more
europepmc   +1 more source

Post-Marketing Reporting Patterns of Ceftazidime-Avibactam and Ceftolozane-Tazobactam: Analysis of Adverse Event Reports from EudraVigilance. [PDF]

open access: yesAntibiotics (Basel)
Gianguzzo VM   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy